Profile data is unavailable for this security.
About the company
Zhejiang Orient Gene Biotech Co., Ltd. is a China-based company principally involved in the research, development, manufacture and sales of in-vitro diagnostic products. The Company's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The Company also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The Company operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.
- Revenue in CNY (TTM)627.03m
- Net income in CNY-414.61m
- Incorporated2005
- Employees2.23k
- LocationZhejiang Orient Gene Biotech Co LtdNo. 3787 East Section of Sunshine AvenueDipu Neighborhood, Anji CountyHUZHOU 313300ChinaCHN
- Phone+86 5 725300267
- Fax+86 5 725300267
- Websitehttps://www.orientgene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Aidea Pharmaceutical Co Ltd | 391.64m | -90.16m | 5.31bn | 476.00 | -- | 4.76 | -- | 13.55 | -0.2106 | -0.2106 | 0.9303 | 2.65 | 0.227 | 1.23 | 1.98 | 822,765.80 | -5.23 | -2.40 | -7.18 | -2.85 | 44.46 | 39.00 | -23.02 | -10.15 | 1.20 | -- | 0.2992 | -- | 68.44 | 8.24 | 38.75 | -- | -4.47 | -- |
| Innovita Biological Technology Co Ltd | 625.12m | 266.22m | 5.50bn | 404.00 | 20.67 | 2.77 | -- | 8.80 | 1.96 | 1.96 | 4.59 | 14.62 | 0.3093 | 1.67 | 6.23 | 1,547,324.00 | 13.17 | -- | 14.20 | -- | 80.99 | -- | 42.59 | -- | 10.66 | -- | 0.0015 | -- | 7.03 | -- | 15.44 | -- | -- | -- |
| Guizhou Sanli Pharmaceutical Co Ltd | 1.71bn | 293.82m | 5.62bn | 2.28k | 19.63 | 3.61 | -- | 3.29 | 0.6988 | 0.6988 | 4.11 | 3.80 | 0.7064 | 2.58 | 3.81 | 748,477.00 | 12.34 | 12.39 | 18.37 | 16.72 | 71.52 | 70.45 | 17.47 | 16.31 | 1.67 | -- | 0.2368 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Zhejiang Orient Gene Biotech Co Ltd | 627.03m | -414.61m | 5.65bn | 2.23k | -- | 0.7672 | -- | 9.01 | -2.05 | -2.05 | 3.11 | 36.51 | 0.065 | 0.9281 | 2.10 | 281,055.40 | -4.58 | 29.62 | -5.53 | 38.29 | 43.94 | 59.69 | -70.46 | 35.82 | 4.27 | -- | 0.0767 | 19.24 | -90.65 | 23.46 | -119.23 | -- | 121.04 | -- |
| Beijing Sun-Novo Pharma Research Co Ltd | 951.95m | 209.57m | 5.65bn | 1.37k | 26.97 | 5.57 | -- | 5.94 | 1.87 | 1.87 | 8.50 | 9.06 | 0.5465 | 26.19 | 1.77 | 694,854.30 | 11.70 | 12.99 | 19.13 | 21.70 | 59.10 | 53.93 | 21.40 | 21.34 | 1.77 | 45.00 | 0.3721 | 10.74 | 37.76 | 47.22 | 18.08 | 54.90 | 34.77 | -- |
| Sichuan Huiyu Pharmaceutical Co Ltd | 931.96m | 147.83m | 5.71bn | 1.36k | 38.63 | 1.50 | -- | 6.13 | 0.349 | 0.349 | 2.20 | 9.01 | 0.2032 | 0.9121 | 14.88 | 683,254.60 | 3.18 | 10.41 | 3.82 | 12.76 | 84.46 | 89.89 | 15.65 | 21.42 | 2.92 | -- | 0.1299 | 20.54 | -37.92 | 76.37 | -43.86 | -- | 66.72 | -- |
Data as of Jun 14 2024. Currency figures normalised to Zhejiang Orient Gene Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
8.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2023 | 6.93m | 3.44% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 2.84m | 1.41% |
| Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 1.94m | 0.96% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 1.50m | 0.74% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 1.36m | 0.67% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.34m | 0.67% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 521.50k | 0.26% |
| Lion Fund Management Co., Ltd.as of 31 Dec 2023 | 509.18k | 0.25% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 493.89k | 0.25% |
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 439.87k | 0.22% |
More ▼
Data from 31 Dec 2023 - 13 Jun 2024Source: FactSet Research Systems Inc.
